Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials

被引:3
作者
Nishi, Takeshi [1 ]
Okada, Kozo [1 ]
Kitahara, Hideki [1 ]
Kameda, Ryo [1 ]
Ikutomi, Masayasu [1 ]
Imura, Shinji [1 ]
Hollak, M. Brooke [1 ]
Yock, Paul G. [1 ]
Popma, Jeffrey J. [2 ]
Kusano, Hajime [3 ]
Cheong, Wai-Fung [3 ]
Sudhir, Krishnankutty [3 ]
Fitzgerald, Peter J. [1 ]
Ellis, Stephen G. [4 ]
Kereiakes, Dean J. [5 ]
Stone, Gregg W. [6 ,7 ]
Honda, Yasuhiro [1 ]
Kimura, Takeshi [8 ]
机构
[1] Stanford Univ, Sch Med, Stanford Cardiovasc Inst, Div Cardiovasc Med, Stanford, CA 94305 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Abbott Vasc, Clin Sci & Med Affairs, Santa Clara, CA USA
[4] Cleveland Clin, Dept Cardiovasc Med, Heart & Vasc Inst, Cleveland, OH 44106 USA
[5] Christ Hosp Heart & Vasc Ctr, Lindner Res Ctr, Cincinnati, OH USA
[6] Cardiovasc Res Fdn, New York, NY USA
[7] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
[8] Kyoto Univ Hosp, Dept Cardiovasc Med, Kyoto, Japan
关键词
Intravascular ultrasound; Bioresorbable vascular scaffold; Drug-eluting stent; CORONARY-ARTERY-DISEASE; ELUTING STENT; CLINICAL-OUTCOMES; THROMBOSIS; STENOSIS; IMPACT;
D O I
10.1016/j.jjcc.2021.03.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The long-term prognostic impact of IVUS findings following Absorb BVS implantation re-mains uncertain. This study aimed to identify the IVUS predictors of long-term clinical outcomes follow-ing ABSORB bioresorbable vascular scaffold (BVS) implantation from the pooled IVUS substudy cohorts of the ABSORB III and Japan trials. Methods: A total of 298 lesions in 286 patients were enrolled with 2:1 randomization to ABSORB BVS vs. cobalt-chromium everolimus-eluting stents. This sub-analysis included 168 lesions of 160 patients in the Absorb arm whose post-procedural quantitative IVUS were available. The primary endpoint of this analysis was device-oriented composite endpoint (DOCE) of target lesion failure, including cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. The median follow-up duration was 4.9 [3.1-5.0] years. Results: During follow-up, DOCE occurred in 10.1% of lesions treated with Absorb BVS. Among several post-procedural IVUS indices associated with DOCE, non-uniform device expansion (defined as unifor-mity index = minimum / maximum device area) (hazard ratio 0.47 per 0.1 increase [95%CI 0.28 to 0.77]; p = 0.003) and residual reference plaque burden (hazard ratio 4.01 per 10% increase [95%CI 1.50 to 10.77]; p = 0.006) were identified as independent predictors of DOCE by Cox multivariable analysis. Conclusions: Nonuniform device expansion and substantial untreated residual plaque in reference seg-ments were associated with long-term adverse events following BVS implantation. Baseline imaging to identify the appropriate device landing zone and procedural imaging to achieve uniform device expan-sion if possible (e.g. through post-dilatation) may improve clinical outcomes of BVS implantation. Clinical trial registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01751906 (ABSORB III); NCT01844284 (ABSORB Japan). (c) 2021 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [41] Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption Five-Year Follow-Up From the ABSORB III Trial
    Kereiakes, Dean J.
    Ellis, Stephen G.
    Metzger, D. Christopher
    Caputo, Ronald P.
    Rizik, David G.
    Teirstein, Paul S.
    Litt, Marc R.
    Kini, Annapoorna
    Kabour, Ameer
    Marx, Steven O.
    Popma, Jeffrey J.
    Tan, Siok Hwee
    Ediebah, Divine E.
    Simonton, Charles
    Stone, Gregg W.
    CIRCULATION, 2019, 140 (23) : 1895 - 1903
  • [42] Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R)
    Nef, Holger
    Wiebe, Jens
    Achenbach, Stefan
    Muenzel, Thomas
    Naber, Christoph
    Richardt, Gert
    Mehilli, Julinda
    Woehrle, Jochen
    Neumann, Till
    Biermann, Janine
    Zahn, Ralf
    Kastner, Johannes
    Schmermund, Axel
    Pfannebecker, Thomas
    Schneider, Steffen
    Limbourg, Tobias
    Hamm, Christian W.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2016, 17 (01) : 34 - 37
  • [43] The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials
    Gogas, Bill D.
    Bourantas, Christos V.
    Garcia-Garcia, Hector M.
    Onuma, Yoshinobu
    Muramatsu, Takashi
    Farooq, Vasim
    Diletti, Roberto
    van Geuns, Robert-Jan M.
    De Bruyne, Bernard
    Chevalier, Bernard
    Thuesen, Leif
    Smits, Pieter C.
    Dudek, Dariusz
    Koolen, Jacques
    Windecker, Stefan
    Whitbourn, Robert
    McClean, Dougal
    Dorange, Cecile
    Miquel-Hebert, Karine
    Veldhof, Susan
    Rapoza, Richard
    Ormiston, John A.
    Serruys, Patrick W.
    EUROINTERVENTION, 2013, 9 (06) : 709 - 720
  • [44] Association of wall shear stress with long-term vascular healing response following bioresorbable vascular scaffold implantation
    Karanasos, Antonios
    Schuurbiers, Johan C. H.
    Garcia-Garcia, HectorM.
    Simsek, Cihan
    Onuma, Yoshinobu
    Serruys, Patrick W.
    Zijlstra, Felix
    van Geuns, Robert-Jan
    Regar, Evelyn
    Wentzel, Jolanda J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 191 : 279 - 283
  • [45] Bioresorbable Vascular Scaffold With Optimized Implantation Technique: Long-Term Outcomes From a Single-Center Experience
    Albani, Stefano
    Giannini, Francesco
    Mitomo, Satoru
    Fabris, Enrico
    Mangieri, Antonio
    Ponticelli, Francesco
    Khokhar, Arif A.
    Toselli, Marco
    Latib, Azeem
    Colombo, Antonio
    JOURNAL OF INVASIVE CARDIOLOGY, 2021, 33 (02) : E115 - E122
  • [46] Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold Optical Coherence Tomography Assessment in the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
    Onuma, Yoshinobu
    Serruys, Patrick W.
    Muramatsu, Takashi
    Nakatani, Shimpei
    van Geuns, Robert-Jan
    de Bruyne, Bernard
    Dudek, Dariusz
    Christiansen, Evald
    Smits, Pieter C.
    Chevalier, Bernard
    McClean, Dougal
    Koolen, Jacques
    Windecker, Stephan
    Whitbourn, Robert
    Meredith, Ian
    Garcia-Garcia, Hector M.
    Veldhof, Susan
    Rapoza, Richard
    Ormiston, John A.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (12) : 1400 - 1411
  • [47] Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial
    Onuma, Yoshinobu
    Sotomi, Yohei
    Shiomi, Hiroki
    Ozaki, Yukio
    Namiki, Atsuro
    Yasuda, Satoshi
    Ueno, Takafumi
    Ando, Kenji
    Furuya, Jungo
    Igarashi, Keiichi
    Kozuma, Ken
    Tanabe, Kengo
    Kusano, Hajime
    Rapoza, Richard
    Popma, Jeffrey J.
    Stone, Gregg W.
    Simonton, Charles
    Serruys, Patrick W.
    Kimura, Takeshi
    EUROINTERVENTION, 2016, 12 (09) : 1090 - 1101
  • [48] Comparison of Long-Term Outcomes Between Intravascular Ultrasound-, Optical Coherence Tomography- and Angiography-Guided Stent Implantation: A Meta-Analysis
    Saylik, Faysal
    Hayiroglu, Mert Ilker
    Akbulut, Tayyar
    Cinar, Tufan
    ANGIOLOGY, 2024, 75 (09) : 809 - 819
  • [49] Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data
    Briede, Ieva
    Narbute, Inga
    Kumsars, Indulis
    Sondore, Dace
    Trushinskis, Karlis
    Jegere, Sanda
    Latkovskis, Gustavs
    Strenge, Karlis
    Rudzitis, Ainars
    Erglis, Andrejs
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2018, 14 (02): : 144 - 148
  • [50] Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist's jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS?
    Serruys, Patrick W.
    Onuma, Yoshinobu
    EUROINTERVENTION, 2017, 12 (17) : 2047 - 2056